Sophiris Bio Inc. announced the appointment of Joseph Turner to its Board of Directors effective and contingent upon the closing of the company's proposed initial U.S. public offering of its common shares and listing on The NASDAQ Stock Market LLC. Mr. Turner has more than 25 years of financial management experience in the biotech and pharmaceutical industries. Mr. Turner currently serves on the Boards of Directors and is the chair of the audit committees of three publicly-traded pharmaceutical companies: Kythera Biopharmaceuticals, Alexza Pharmaceuticals, Inc. and Corcept Therapeutics, Inc. From 1999 to 2006, Mr. Turner spent seven years as Chief Financial Officer at Myogen, Inc., until the sale of the company to Gilead Sciences.